CSTL
CASTLE BIOSCIENCES INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$32.17
+0.64%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$32.44
From 52W high−25.27%
Volume319814.00
Market cap$982.62M
P/E (TTM)—
P/S (TTM)2.8x
Div yield—
Key dataOct 19, 2026
Open
$32.44
From 52W high
−25.27%
Volume
319814.00
Market cap
$982.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−232.5x
P/E (TTM)
—
RSI (14)
42.7
MomentumView details →
1D Return
+0.64%
YTD Return
−17.28%
SummaryUpdated Jun 1, 2026
Castle Biosciences, Inc. (NASDAQ:CSTL) is a commercial-stage diagnostics company founded in 2007 and headquartered in Friendswood, Texas. The company went public in July 2019 and has established itself as a leading provider of gene expression profile (GEP) tests for various medical conditions, with a primary focus on dermatological cancers. Castle has evolved from a single-product company focused on melanoma testing to a diversified diagnostics platform serving dermatology, gastroenterology, and mental health markets through both organic growth and strategic acquisitions.
Similar companies
Latest newsMore news →
Castle Biosciences announced that it will release financial results for the third quarter and nine months ended September 30, 2026, after market close on November 5, 2026.5d agoCastle Biosciences announced that data from three studies evaluating its TissueCypher Barrett's Esophagus test will be presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.7d agoCastle Biosciences announced the publication of a study showing its TissueCypher Barrett's Esophagus Test changed management for 90% of patients with non-dysplastic Barrett's esophagus at an expert surgery center.22d ago